

# **Executive Officer Notice:**

## **Inflectra® temporary PIN**

**April 30, 2025**

This Executive Officer (EO) Notice provides important updates regarding the funding of Inflectra®, the biosimilar to Remicade®.

As of March 31, 2023, Ontario Drug Benefit (ODB) Program recipients using select originator biologics, including Remicade®, began transitioning to a Health Canada-approved biosimilar, such as Inflectra®, within designated transition periods.

The market authorization holder for Inflectra® (infliximab) is Celltrion Inc., but Pfizer Canada ULC has rights to distribute Inflectra® in Canada until September 30, 2025.

On April 1, 2025, Celltrion Inc. resumed selling its infliximab biosimilar in Canada under the name Remdantry™. Remdantry™ has the same Drug Identification Number (DIN) as Inflectra® (DIN 02419475).

On April 30, 2025, Remdantry™ will be designated as a limited use benefit on the ODB Formulary with DIN 02419475. To differentiate Remdantry™ from Inflectra® for billing purposes, Inflectra® will be assigned Product Identification Number (PIN) 09858358 in the same Formulary update.

After September 30, 2025, Inflectra® will be discontinued and Remdantry™ will continue to be sold under DIN 02419475.

**Therefore, prior to April 30, 2025:**

- Remdantry™ is *not* funded under the ODB program and *cannot* be billed to the ODB Program; and
- Inflectra® is funded as a limited use benefit and can be billed to the ODB Program using DIN 02419475.

**As of April 30, 2025:**

- Remdantry™ will be funded as a limited use benefit and can be billed to the ODB Program using DIN 02419475; and

- Inflectra® will continue to be funded as a limited use benefit but can only be billed to the ODB Program using PIN 09858358.

**Finally, after September 30, 2025:**

- Once the remaining supply of discontinued Inflectra® has been depleted from the marketplace, Inflectra® will be delisted from the Formulary.

The above rules are summarized in the table below to help guide claim submissions.

**DIN/PIN for Claim Submission:**

Biosimilar	Up to April 29, 2025	Effective April 30, 2025
Inflectra®	DIN 02419475	PIN 09858358 (Until product delisting post-September 30, 2025)
Remdantry™	Not a Benefit	DIN 02419475

Prescription Requirements

A new prescription will not be required for ODB Program recipients transitioning between Inflectra® and Remdantry™, as both products share the same DIN and only the marketed brand **name** has changed. However, the prescription on file must have the applicable Reason for Use code as Inflectra® and Remdantry™ will both be limited use benefits.

For further details, please refer to [Ontario's Formulary](#) updates or contact the Ministry of Health.

**Additional Information:**

**For pharmacies:**

For billing inquiries, please call ODB Pharmacy Help Desk at: 1-800-668-6641

**For all other Health Care Providers and the Public:**

Please call ServiceOntario, Infoline at 1-866-532-3161 TTY 1-800-387-5559. In Toronto, TTY 416-327-4282

All other inquiries regarding the biosimilar policy should be directed to [DrugProgramsDelivery@ontario.ca](mailto:DrugProgramsDelivery@ontario.ca)